logo
Plus   Neg
Share
Email

Galena Biopharma CEO Mark Ahn Steps Down; Names Mark Schwartz Replacement

Galena Biopharma Inc. (GALE) Thursday said Mark Ahn, its President and Chief Executive Officer, has resigned from the company to pursue other goals. Mark Schwartz will take over the position, effective immediately.

Previously, Schwartz was Galena's Executive Vice President and Chief Operating Officer. He has over 30 years of experience in the biotechnology and life science industry. Before joining Galena, he had served in the roles of President and Chief Executive at Apthera Inc. and at Bayhill Therapeutics. He was also the President and CEO of Calyx Therapeutics, which expanded significantly, and completed key Phase 1 and Phase 2 international clinical trials of novel anti-inflammatory compounds during his tenure.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT